Sonidegib

Brand names: Odomzo · Active ingredient: Sonidegib Phosphate

In short: ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

Forms & strengthsCapsules: 200 mg, opaque pink colored with ‘SONIDEGIB 200MG’ printed on the body and ‘NVR’ printed on the cap in black ink (equivalent to 281 mg of diphosphate salt of sonidegib).
LabelSun Pharmaceutical Industries, Inc.
Label updatedJan 03, 2025

What is Sonidegib used for?

ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

âš  Boxed warning (FDA's strongest warning)

ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ODOMZO is embryotoxic, fetotoxic, and teratogenic in animals

.

Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose

.

Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose

.

Sonidegib dosage

Verify the pregnancy status of females of reproductive potential prior to initiating ODOMZO .

The recommended dosage of ODOMZO is 200 mg taken orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, administered until disease progression or unacceptable toxicity .

Obtain serum creatine kinase (CK) levels and renal function tests prior to initiating ODOMZO in all patients .

If a dose of ODOMZO is missed, resume dosing with the next scheduled dose.

Interrupt ODOMZO for

Severe or intolerable musculoskeletal adverse reactions.

First occurrence of serum CK elevation between 2.5 and 10 times upper limit of normal (ULN).

Recurrent serum CK elevation between 2.5 and 5 times ULN.

Resume ODOMZO at 200 mg daily upon resolution of clinical signs and symptoms.

Permanently discontinue ODOMZO for

Serum CK elevation greater than 2.5 times ULN with worsening renal function.

Serum CK elevation greater than 10 times ULN.

Recurrent serum CK elevation greater than 5 times ULN.

Recurrent severe or intolerable musculoskeletal adverse reactions.

How to take Sonidegib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Medication Guide

).

Embryo-Fetal Toxicity

[see

Warnings and Precautions (5.1)

and

Use in Specific Populations (8.1,

8.3)

].

Females of Reproductive Potential

Advise female patients of the potential risk to a fetus. Advise female patients and female partners of male patients to contact their healthcare provider with a known or suspected pregnancy.

Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose.

Advise females who may have been exposed to ODOMZO during pregnancy, either directly or through seminal fluid, to contact Sun Pharmaceutical Industries Inc. at 1-800-406-7984.

Males

Advise males, even those with prior vasectomy, to use condoms, to avoid potential drug exposure in both pregnant partners and female partners of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose.

Blood Donation

Advise patients not to donate blood or blood products while taking ODOMZO and for 20 months after stopping treatment. …

Warnings & precautions

Do not take this medicine if: None.

ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. In animal reproduction studies, sonidegib was embryotoxic, fetotoxic, and teratogenic at maternal exposures below the recommended human dose of 200 mg .

Females of Reproductive Potential

Verify pregnancy status of females of reproductive potential prior to initiating ODOMZO treatment. Advise pregnant women of the potential risk to a fetus. Advise females to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose .

Males

Advise male patients with female partners to use condoms, even after a vasectomy, during treatment with ODOMZO and for at least 8 months after the last dose to avoid potential drug exposure in pregnant females or females of reproductive potential .

Blood Donation

Advise patients not to donate blood or blood products while taking ODOMZO and for at least 20 months after the last dose of ODOMZO, because their blood or blood products might be given to a female of reproductive potential.

Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase (CK) elevations, occur with ODOMZO and other drugs which inhibit the hedgehog (Hh) pathway.

In a pooled safety analysis of 12 clinical studies involving 571 patients with various advanced cancers treated with ODOMZO at doses ranging from 100 mg to 3000 mg, rhabdomyolysis (defined as serum CK increase of more than ten times the baseline value with a concurrent 1.5-fold or greater increase in serum creatinine above baseline value) occurred in one patient (0.2%) treated with ODOMZO 800 mg.

In the BOLT study, musculoskeletal adverse reactions occurred in 68% (54/79) of patients treated with ODOMZO 200 mg daily with 9% (7/79) reported as Grade 3 or 4. …

Sonidegib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Musculoskeletal Adverse Reactions .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of ODOMZO was evaluated in BOLT, a randomized, double-blind, multiple cohort trial in which 229 patients received ODOMZO at either 200 mg (n=79) or 800 mg (n=150) daily. The frequency of common adverse reactions including muscle spasms, alopecia, dysgeusia, fatigue, nausea, decreased weight, decreased appetite, myalgia, pain, and vomiting was greater in patients treated with ODOMZO 800 mg as compared to 200 mg.

The data described below reflect exposure to ODOMZO 200 mg daily in 79 patients with locally advanced BCC (laBCC; n=66) or metastatic BCC (mBCC; n=13) enrolled in BOLT. Patients were followed for at least 18 months unless discontinued earlier. The median duration of treatment with ODOMZO was 11.0 months (range 1.3 to 33.5 months).

The study population characteristics were: median age of 67 years (range 25 to 92; 59% were ≥65 years), 61% male, and 90% white. The majority of patients had prior surgery (75%), radiotherapy (24%), systemic chemotherapy (4%), or topical or photodynamic therapies (18%) for treatment of BCC. …

Drug interactions

Strong and Moderate CYP3A Inhibitors

Avoid concomitant administration of ODOMZO with strong CYP3A inhibitors .

Avoid concomitant administration of ODOMZO with moderate CYP3A inhibitors. If a moderate CYP3A inhibitor must be used, administer the moderate CYP3A inhibitor for less than 14 days and monitor closely for adverse reactions particularly musculoskeletal adverse reactions .

Strong and Moderate CYP3A Inducers

Avoid concomitant administration of ODOMZO with strong and moderate CYP3A inducers .

About this medicine

Sonidegib is a Hh pathway inhibitor. The molecular formula for sonidegib phosphate is C26H26 F3N3O3• 2H3PO4. The molecular weight is 681.49 daltons. The chemical name is N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4’-(trifluoromethoxy) [1,1’-biphenyl]-3-carboxamide diphosphate. The molecular structure is shown below:

Sonidegib phosphate is a white to off-white powder. Sonidegib freebase is practically insoluble.

ODOMZO (sonidegib) capsules for oral use contain 200 mg of sonidegib as the freebase (equivalent to 281 mg of diphosphate salt of sonidegib) and the following inactive ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, poloxamer and sodium lauryl sulfate. The opaque pink hard gelatin capsule shell contains gelatin, red iron oxide, and titanium dioxide. The black printing ink contains ammonium hydroxide, black iron oxide, propylene glycol, and shellac.

How it works: Sonidegib is an inhibitor of the Hh pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 028312dc-d155-4fd5-8abd-6bb9f011d3cc. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate